- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Results from DAPA-CKD: Time-to-Event and Cost Consequence
An expert in chronic kidney disease (CKD) discusses the importance of showing data at the 3-year mark for the DAPA-CKD study, released at AMCP.
EP: 1.CKD: Healthcare Resource Utilization
EP: 2.New Data From AMCP: DAPA-CKD Study
EP: 3.Findings From the DAPA-CKD Study: Reductions in Healthcare Resource Utilization
EP: 4.Analysis from DAPA-CKD: Time-to-Event and Cost Consequence
EP: 5.Results from DAPA-CKD: Time-to-Event and Cost Consequence
EP: 6.Implications of Dapagliflozin Analysis in CKD
EP: 7.IgA Nephropathy Data: US Incident Population
EP: 8.Clinical and Humanistic Burden of IgA Nephropathy
EP: 9.Changing Practice Patterns in CKD
Robert Toto, MD: What is the importance of showing the data of the savings at the 3-year mark when the model was carried out for 4 years? It’s important to show data all along the way. The average time on the study was less than 3 years because the DAPA-CKD study was stopped early by the data monitoring committee for overwhelming efficacy. The data monitoring committee monitors the safety of clinical trials, and if they see that a drug is saving lives, they recommend stopping the study. It would be unethical to continue a study if you know that you have a life-saving treatment. Adversely, if a drug is causing harm, then the data monitoring committee stops the study for that reason. The importance of looking at this at the 3-year mark is that if you look at the kidney function in patients with chronic kidney disease over time, there’s a lot of variability in the rate in which patients decline, even with patients who have the same disease with similar blood pressures. When you take a 3-year time frame, and you look at that in and of itself as a valued marker, that 3-year time frame would encompass a lot of events that you would see in the study. It would encompass a lot of the costs related to the care of patients within that 3-year time frame.
Transcript edited for clarity.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen
![[Nurse recording dialysis] Credit: iStock](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd0325805e4fd25df9227eeacb118e8ccbaf0dd99-612x408.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[Nurse recording dialysis] Credit: iStock")
